Anamorelin hydrochloride is under clinical development by Helsinn Healthcare and currently in Phase II for Chemotherapy Effects. According to GlobalData, Phase II drugs for Chemotherapy Effects have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Anamorelin hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Anamorelin hydrochloride overview

Anamorelin hydrochloride (Adlumiz) is a synthetic, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. It is formulated as film coated tablets for oral route of administration. Adlumiz is indicated for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer.

Anamorelin hydrochloride (RC-1291, ONO-7643) is under development for the treatment of cancer cachexia/anorexia in non-small cell lung cancer (NSCLC) patients and cancer-related fatigue. It is a new molecular entity which is formulated as a tablet and is administered orally. The drug candidate acts by targeting the ghrelin receptor.

It was also under development for the treatment of cancer cachexia/anorexia in EU.

Helsinn Healthcare overview

Helsinn Healthcare, a subsidiary of Helsinn Holding SA, is a cancer care company that offers oncology products and therapies. The company focuses on research and development, drug discovery and manufacturing of formulations of drug products in therapeutic areas of pain and inflammation, cancer supportive care and gastroenterology. Its products comprise Aloxi, Gelclair, Akynzeo, Nimesulide, Klean-Prep and laxaclear. The company also offers integrated early and late-stage licensing programs for its own drug discovery and development programs. It operates R&D and production facilities in Dublin, Ireland and Biasca, Switzerland and supplies products across the US, Monaco, Japan and China. Helsinn Healthcare is headquartered in Lugano, Switzerland.

For a complete picture of Anamorelin hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.